https://www.selleckchem.com/pr....oducts/caffeic-acid-
Background Fingolimod (Gilenya®) is approved for adult and pediatric patients with highly active relapsing-remitting multiple sclerosis (RRMS). Objectives The objective was to describe the effectiveness of fingolimod in young adults compared to older patients in clinical practice. Methods PANGAEA is the largest prospective, multi-center, non-interventional, long-term study evaluating fingolimod in RRMS. We descriptively analyzed demographics, MS characteristics, and severity in two subgroups of young adults (≤20 and
Like
Comment
Share
